Company Profile
Ensysce Biosciences Stock Price, News & Analysis
- Ticker:
- ENSC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.52 USD (+44.83%)
Close
Last updated: August 6, 2026
3.84M USD
Market cap
Why the stock is moving
Following the latest company update, “Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing”, ENSC closed up 44.8% at $0.5243 on Aug 6, 2026. The move occurred in the trading session associated with this financing update.
Company overview
Business overview
Ensysce Biosciences is a biotechnology company focused on abuse-deterrent and safer opioid-related technologies. Its story is built around opioid safety, pain management, and formulation science.
Geographic Base and Sector Classification
Ensysce is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a pain-safety focus.
Business Model Characteristics
The company depends on clinical and regulatory progress, platform validation, and the ability to commercialize safer pain solutions. Investors usually watch proof-of-concept data, safety, and commercialization strategy.
Position Within the Biotechnology Landscape
Ensysce occupies a niche pain-safety position within biotech. The stock is driven by whether its formulation platform can matter in a high-need opioid market.
Future catalysts
The cleaner way to frame Ensysce Biosciences right now is around MPAR-102 in and central nervous system therapeutics engineered to minimi.... The most useful line from the latest update is (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize.... That should keep the program at the center of the company narrative for now. The partnership angle also matters here, especially around In parallel, our Board has initiated a formal review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate the development of our....
Recent news
- 01
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Source: Ensysce Biosciences
- 02
- 03
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Source: Ensysce Biosciences
- 04
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Source: Ensysce Biosciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ensysce Biosciences (ENSC)?
Ensysce Biosciences (ENSC) most recently closed at 0.52 USD, a +44.83% move versus the previous session.
What is the market cap of Ensysce Biosciences (ENSC)?
Ensysce Biosciences currently has a market capitalization of 3.84M USD on BioPharmSignal.
What does Ensysce Biosciences do?
Ensysce Biosciences is a biotechnology company focused on abuse-deterrent and safer opioid-related technologies. Its story is built around opioid safety, pain management, and formulation science.
On which exchange is ENSC stock listed?
Ensysce Biosciences (ENSC) is associated with NASDAQ, United States, Biopharma.
What is MPAR-102?
The cleaner way to frame Ensysce Biosciences right now is around MPAR-102 in and central nervous system therapeutics engineered to minimi....
Which conditions is Ensysce Biosciences targeting with MPAR-102?
The cleaner way to frame Ensysce Biosciences right now is around MPAR-102 in and central nervous system therapeutics engineered to minimi....
How does Ensysce Biosciences describe recent progress with MPAR-102?
The cleaner way to frame Ensysce Biosciences right now is around MPAR-102 in and central nervous system therapeutics engineered to minimi....
What is Ensysce?
Ensysce Biosciences is a biotechnology company focused on abuse-deterrent and safer opioid-related technologies.